Prevalence and characteristics of moderate to severe fatigue: A multicenter study in cancer patients and survivors

Cancer

Volumn 120, Issue 3, 2014, Pages 425-432

  Wang, Xin Shelley ^a   Zhao, Fengmin ^b   Fisch, Michael J ^a   O'Mara, Ann M ^c   Cella, David ^d   Mendoza, Tito R ^a   Cleeland, Charles S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

fatigue; M. D. Anderson Symptom Inventory (MDASI); patient reported outcome; practice guidelines; survivorship

Indexed keywords

OPIATE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER SURVIVOR; CLINICAL ASSESSMENT TOOL; COLORECTAL CANCER; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; FATIGUE; FEMALE; HUMAN; LUNG CANCER; M. D. ANDERSON SYMPTOM INVENTORY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTPATIENT; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; RATING SCALE; REGRESSION ANALYSIS; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FATIGUE; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASMS; PREVALENCE; SURVIVORS;

EID: 84892940018     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28434     Document Type: Article

References (29)

1. Yanez B, Pearman T, Lis CG, Beaumont JL, Cella D,. The FACT-G7: a rapid version of the functional assessment of cancer therapy-general (FACT-G) for monitoring symptoms and concerns in oncology practice and research. Ann Oncol. 2013; 24: 1073-1078.
2. Wang XS, Cleeland CS, Mendoza TR, et al. Impact of cultural and linguistic factors on symptom reporting by patients with cancer. J Natl Cancer Inst. 2010; 102: 732-738.
3. Minton O, Strasser F, Radbruch L, Stone P,. Identification of factors associated with fatigue in advanced cancer: a subset analysis of the European palliative care research collaborative computerized symptom assessment data set. J Pain Symptom Manage. 2012; 43: 226-235.
4. Mendoza TR, Wang XS, Cleeland CS, et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer. 1999; 85: 1186-1196.
5. Servaes P, Gielissen MF, Verhagen S, Bleijenberg G,. The course of severe fatigue in disease-free breast cancer patients: a longitudinal study. Psychooncology. 2007; 16: 787-795.
6. Pachman DR, Barton DL, Swetz KM, Loprinzi CL,. Troublesome symptoms in cancer survivors: fatigue, insomnia, neuropathy, and pain. J Clin Oncol. 2012; 30: 3687-3696.
7. Minton O, Richardson A, Sharpe M, Hotopf M, Stone P,. A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. J Natl Cancer Inst. 2008; 100: 1155-1166.
8. Hofman M, Morrow GR, Roscoe JA, et al. Cancer patients' expectations of experiencing treatment-related side effects: a University of Rochester Cancer Center-Community Clinical Oncology Program study of 938 patients from community practices. Cancer. 2004; 101: 851-857.
9. Patrick DL, Ferketich SL, Frame PS, et al. National Institutes of Health State-of-the-Science Conference Statement: symptom management in cancer: pain, depression, and fatigue, July 15-17, 2002. J Natl Cancer Inst Monogr. 2004;(32): 9-16.
10. Cella D, Davis K, Breitbart W, Curt G,. Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol. 2001; 19: 3385-3391.
11. Cella D, Lai JS, Chang CH, Peterman A, Slavin M,. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer. 2002; 94: 528-538.
12. US Food and Drug Administration. Guidance for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM071975.pdf. Accessed July 31, 2012.
13. Berger AM, Abernethy AP, Atkinson A, et al. NCCN Practice Guidelines in Oncology: Cancer-Related Fatigue. nccn.org/professionals/physician-gls/PDF/ fatigue.pdf. Accessed July 17, 2013.
14. Howell D, Keller-Olaman S, Oliver TK, et al. A Pan-Canadian Practice Guideline: Screening, Assessment and Care of Cancer-Related Fatigue in Adults With Cancer. capo.ca/Fatigue-Guideline.pdf. Accessed August 21, 2013.
15. Barsevick AM, Cleeland CS, Manning DC, et al. ASCPRO (Assessing Symptoms of Cancer Using Patient-Reported Outcomes). ASCPRO recommendations for the assessment of fatigue as an outcome in clinical trials. J Pain Symptom Manage. 2010; 39: 1086-1099.
16. Anderson KO,. Role of cutpoints: why grade pain intensity? Pain. 2005; 113: 5-6.
17. Oldenmenger WH, de Raaf PJ, de Klerk C, van der Rijt CC,. Cut points on 0-10 numeric rating scales for symptoms included in the Edmonton Symptom Assessment Scale in cancer patients: a systematic review. J Pain Symptom Manage. 2013; 45: 1083-1093.
18. Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS,. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain. 1995; 61: 277-284.
19. Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer. 2000; 89: 1634-1646.
20. StataCorp LP,. Stata Statistical Software, version 11 [computer program]. College Station TX: StataCorp LP; 2009.
21. Wang XS,. Cancer-related fatigue. In:, Berger AM, Shuster JL, von Roenn JH, eds. Principles and Practice of Palliative Care and Supportive Oncology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2013: 84-95.
22. Bower JE, Ganz PA, Desmond KA, Rowland JH, Meyerowitz BE, Belin TR,. Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J Clin Oncol. 2000; 18: 743-753.
23. Given B, Given CW, Sikorskii A, et al. Establishing mild, moderate, and severe scores for cancer-related symptoms: how consistent and clinically meaningful are interference-based severity cut-points? J Pain Symptom Manage. 2008; 35: 126-135.
24. Basch E,. The missing voice of patients in drug-safety reporting. N Engl J Med. 2010; 362: 865-869.
25. Jean-Pierre P, Morrow GR, Roscoe JA, et al. A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. Cancer. 2010; 116: 3513-3520.
26. Moraska AR, Sood A, Dakhil SR, et al. Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial. J Clin Oncol. 2010; 28: 3673-3679.
27. US Census Bureau. ACS Demographic and Housing Estimates: 2010 American Community Survey 1-year Estimates. factfinder2.census.gov/faces/tableservices/ jsf/pages/productview.xhtml. Accessed August 21, 2013.
28. Farrar JT,. Cut-points for the measurement of pain: the choice depends on what you want to study. Pain. 2010; 149: 163-164.
29. Hirschfeld G, Zernikow B,. Variability of "optimal" cut points for mild, moderate, and severe pain: neglected problems when comparing groups. Pain. 2013; 154: 154-159.